Reolysin is an oncolytic virus commercialized by Oncolytics Biotech, with a leading Phase II program in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer). According to Globaldata, it is involved in 49 clinical trials, of which 40 were completed, 5 are ongoing, 2 are planned, and 2 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Reolysin’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Reolysin is expected to reach an annual total of $109 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Reolysin Overview
Oncolytics Biotech Overview
Oncolytics Biotech (Oncolytics) is a biopharmaceutical company. It is developing pelareorep, an intravenous immunotherapeutic agent derived from a non-pathogenic reovirus. This treatment activates both innate and adaptive immune systems, enhancing anti-tumor responses and increasing susceptibility to various oncology treatments. The company is advancing pelareorep in hormone receptor-positive, HER2-negative metastatic breast cancer and metastatic pancreatic ductal adenocarcinoma. It is also exploring gastrointestinal cancers through its GOBLET platform study, having completed enrollment in cohorts for advanced pancreatic ductal adenocarcinoma, third-line colorectal cancer, and actively enrolling in an advanced anal cancer cohort. Oncolytics is headquartered in Calgary, Alberta, Canada.
The operating loss of the company was CAD33.8 million in FY2023, compared to an operating loss of CAD26.9 million in FY2022. The net loss of the company was CAD27.8 million in FY2023, compared to a net loss of CAD24.8 million in FY2022.
For a complete picture of Reolysin’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
